spracticeХирургическая практикаSurgical practice (Russia)2223-2427АНО "Консорциум "Медицинская техника"10.38181/2223-2427-2021-4-68-80spractice-269Research ArticleСтатьиРОЛЬ УРОКИНАЗНОЙ СИСТЕМЫ В ЛИМФОГЕННОМ МЕТАСТАЗИРОВАНИИ КОЛОРЕКТАЛЬНОГО РАКАTHE ROLE OF THE UROKINASE SYSTEM IN LYMPHOGENOUS METASTASIS OF COLORECTAL CANCERhttps://orcid.org/0000-0002-6569-7078АгаповМ. А.AgapovM. A.

Агапов Михаил Андреевич – доктор мед. наук, профессор, профессор кафедры хирургии

ул. Ленинские Горы, д. 1, 119991, Москва

Mikhail A. Agapov – PhD, Professor of the Department of Surgery

st. Leninskie Gory, 1, 119991, Moscow

getinfo911@mail.ruhttps://orcid.org/0000-0002-7055-9008КривоносоваД. А.KrivonosovaD. A.

Кривоносова Дарья Александровна – клинический ординатор отделения хирургии №1 медицинского научно-образовательного центра

ул. Ленинские Горы, д. 1, 119991, Москва

Daria A. Krivonosova – Clinical Resident of the Department of Surgery No. 1 of the Medical Scientific and Educational Center of the Moscow State University

st. Leninskie Gory, 1, 119991, Moscow

dachette-2010@mail.ruhttps://orcid.org/0000-0002-3927-9286СеминаЕ. В.SeminaE. V.

Семина Екатерина – ведущий научный сотрудник ФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава России, НИИ экспериментальной кардиологии, лаборатория молекулярной эндокринологии

ул. Ленинские Горы, д. 1, 119991, Москва

Ekaterina V. Semina – Leading Researcher, National Research Medical Center for Cardiology, Ministry of Health of Russia, Research Institute of Experimental Cardiology, Laboratory of Molecular Endocrinology

st. Leninskie Gory, 1, 119991, Moscow

semina@yandex.ruhttps://orcid.org/0000-0003-0352-2317КакоткинВ. В.KakotkinV. V.

Какоткин Виктор Викторович – научный сотрудник отдела хирургии МНОЦ

ул. Ленинские Горы, д. 1, 119991, Москва

Viktor V. Kakotkin – Researcher, Department of Surgery, Moscow State University Medical Center. M.V. Lomonosov

st. Leninskie Gory, 1, 119991, Moscow

axtroz4894@gmail.comhttps://orcid.org/0000-0003-2330-4229ГармановаТ. Н.GarmanovaT. N.

Гарманова Татьяна Николаевна – к.м.н., доцент кафедры хирургии

ул. Ленинские Горы, д. 1, 119991, Москва

Tatiana N. Garmanova – PhD, docent of the Department of Surgery

st. Leninskie Gory, 1, 119991, Moscow

tatianagarmanova@gmail.comhttps://orcid.org/0000-0003-2711-2400МаркарьянД. Р.MarkaryanD. R.

Маркарьян Даниил Рафаэлевич – к.м.н., доцент кафедры хирургии

ул. Ленинские Горы, д. 1, 119991, Москва

Daniil R. Markaryan – PhD, docent of the Department of Surgery

st. Leninskie Gory, 1, 119991, Moscow

dmarkaryan@gmail.comhttps://orcid.org/0000-0002-6359-0998ГаллямовЭ. А.GallyamovE. A.

Галлямов Эдурад Абдулхаевич – д.м.н., профессор, заведующий кафедрой общей хирургии, Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)

ул. Ленинские Горы, д. 1, 119991, Москва

Gallyamov Edurad Abdulkhaevich – DM,  PhD,  Professor, Head of the Department of General Surgery, I.M. Sechenov (Sechenov University)

st. Leninskie Gory, 1, 119991, Moscow

https://orcid.org/0000-0002-8260-5542КлимовичП. С.KlimovichP. S.

Климович Полина Сергеевна – научный сотрудник ФГБУ Национальный медицинский исследовательский центр кардиологии Минздрава России, НИИ экспериментальной кардиологии, лаборатория молекулярной эндокринологии

ул. Ленинские Горы, д. 1, 119991, Москва

Klimovich Polina Sergeevna – researcher, National Medical Research Center for Cardiology, Ministry of Health of Russia, Research Institute of Experimental Cardiology, Laboratory of Molecular Endocrinology

st. Leninskie Gory, 1, 119991, Moscow

lex2050@mail.ruМосковский государственный университет имени М.В. Ломоносова, факультет фундаментальной медицины (МГУ имени М.В. Ломоносова)РоссияMoscow State University named after M.V. Lomonosov, Faculty of Fundamental Medicine (Lomonosov Moscow State University)Russian Federation202117122021046880Copyright © Агапов М.А., Кривоносова Д.А., Семина Е.В., Какоткин В.В., Гарманова Т.Н., Маркарьян Д.Р., Галлямов Э.А., Климович П.С., 20212021Агапов М.А., Кривоносова Д.А., Семина Е.В., Какоткин В.В., Гарманова Т.Н., Маркарьян Д.Р., Галлямов Э.А., Климович П.С.Agapov M.A., Krivonosova D.A., Semina E.V., Kakotkin V.V., Garmanova T.N., Markaryan D.R., Gallyamov E.A., Klimovich P.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.spractice.ru/jour/article/view/269

Целью: данной работы стало изучение роли и взаимосвязи уровней компонентов урокиназной системы с лимфогенным метастатизированием у пациентов с колоректальным раком.Материалы и методы: исследование было проведено на базе «Медицинского научно-образовательного центра МГУ имени М.В. Ломоносова» с 2019 по 2021 год. В исследование были включены здоровые доноры (контрольная группа) и пациенты с верифицированным диагнозом колоректальный раком I-III стадии в соответствие с критериями включения, всем пациентам была проведена проведена хирургическая резекция первичной опухоли с лимфодиссекцией соответствующего уровня. У всех пациентов было проведено определение уровня uPA и uPAR в сыворотке крови до оперативного лечения. Также были проанализированы клинико-демографические данные пациентов, а также патоморфологические характеристики опухоли.Результаты. В исследование были включены 7 здоровых доноров и 49 пациентов с колоректальным раком I-III стадии. Средний уровень урокиназы сыворотки крови в контрольном группе составил 2,7±1,04нг/мл, в исследуемой группе – 4, 15±1,9 нг/мл (р=0,071), уровень рецептора урокиназы в контрольной и исследуемый группе 1,36±0,8 нг/мл vs 3,22±2,06 нг/мл (р=0,05). Средний уровень урокиназы сыворотки крови у пациентов без и с поражением лимфатических узлов составил 3,4±1,4нг/мл и 4,4±2,3 нг/мл (р=0,068).Заключение. Имеется тенденция повышения уровня компонентов урокиназной системы в периферической крови у пациентов с новообразованиями толстой кишки в дооперационном периоде в зависимости наличия метастатического поражения регионарных лимфоузлов, что говорит о необходимости дальнейших исследований по данному направлению.

The aim of this work was to study the role and relationship of the levels of the components of the urokinase system with lymphogenous metastasis in patients with colorectal cancer.Materials and methods: the study was carried out on the basis of the Medical Scientific and Educational Center of the Moscow State University named after M.V. Lomonosov from 2019 to 2021. The study included healthy donors (control group) and patients with a verified diagnosis of stage I-III colorectal cancer in accordance with the inclusion criteria; all patients underwent surgical resection of the primary tumor with lymphadenectomy of the appropriate level. All patients underwent determination of the level of uPA and uPAR in blood serum before surgery. We also analyzed the clinical and demographic data of the patients, as well as the pathomorphological characteristics of the tumor.Results. The study included 7 healthy donors and 49 patients with stage I-III colorectal cancer. The average level of serum urokinase in the control group was 2.7±1.04 ng / ml, in the study group – 4, 15±1.9 ng / ml (p = 0.071), the level of the urokinase receptor in the control and study groups was 1.36 ±0.8 ng / ml vs 3.22±2.06 ng / ml (p = 0.05). The average level of serum urokinase in patients without and with lesions of lymph nodes was 3.4±1.4 ng / ml and 4.4±2.3 ng / ml (p = 0.068).Conclusion. There is a tendency to an increase in the level of components of the urokinase system in the peripheral blood in patients with colon neoplasms in the preoperative period, depending on the presence of metastatic lesions of regional lymph nodes, which indicates the need for further research in this area.

колоректальный ракурокиназная системалимфогенное метастазированиеурокиназарак прямой кишкирак ободочной кишкиcolorectal cancerurokinase systemlymphogenous metastasisurokinaserectal cancercolon cancerReferencesSeydaoğlu G, Özer B, Arpacı N, Parsak CK, Eray IC. Trends in colorectal cancer by subsite, age, and gender over a 15-year period in Adana, Turkey: 1993-2008. Turk J Gastroenterol. 2013;24(6):521-31. https://doi.org/10.4318/tjg.2013.0726Seydaoğlu G, Özer B, Arpacı N, Parsak CK, Eray IC. Trends in colorectal cancer by subsite, age, and gender over a 15-year period in Adana, Turkey: 1993-2008. Turk J Gastroenterol. 2013;24(6):521-31. https://doi.org/10.4318/tjg.2013.0726Thörn M, Bergström R, Kressner U, Sparén P, Zack M, Ekbom A. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birth cohort. Cancer Causes Control. 1998 Mar;9(2):145-52. https://doi.org/10.1023/a:1008826109697Thörn M, Bergström R, Kressner U, Sparén P, Zack M, Ekbom A. Trends in colorectal cancer incidence in Sweden 1959-93 by gender, localization, time period, and birth cohort. Cancer Causes Control. 1998 Mar;9(2):145-52. https://doi.org/10.1023/a:1008826109697Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001 Sep;2(9):533-43. https://doi.org/10.1016/S1470-2045(01)00486-7Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001 Sep;2(9):533-43. https://doi.org/10.1016/S1470-2045(01)00486-7Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020 Jul;70(4):313. https://doi.org/10.3322/caac.21609Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020 Jul;70(4):313. https://doi.org/10.3322/caac.21609Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2005 AprJun;20(2):93-102.Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers. 2005 AprJun;20(2):93-102.Yang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer. 2000 Sep 20;89(5):431-9. https://doi.org/10.1002/1097-0215(20000920)89:5<431::aid-ijc6>3.0.co;2-vYang JL, Seetoo Dq, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. Int J Cancer. 2000 Sep 20;89(5):431-9. https://doi.org/10.1002/1097-0215(20000920)89:5<431::aid-ijc6>3.0.co;2-vHannocks MJ, Oliver L, Gabrilove JL, Wilson EL. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood. 1992 Mar 1;79(5):1178-84.Hannocks MJ, Oliver L, Gabrilove JL, Wilson EL. Regulation of proteolytic activity in human bone marrow stromal cells by basic fibroblast growth factor, interleukin-1, and transforming growth factor beta. Blood. 1992 Mar 1;79(5):1178-84.Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. 1999 Jul 15;94(2):649-62.Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. 1999 Jul 15;94(2):649-62.Mukhina S, Stepanova V, Traktouev D, Poliakov A, Beabealashvilly R, Gursky Y, Minashkin M, Shevelev A, Tkachuk V. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem. 2000 Jun 2;275(22):16450-8. https://doi.org/10.1074/jbc.M909080199Mukhina S, Stepanova V, Traktouev D, Poliakov A, Beabealashvilly R, Gursky Y, Minashkin M, Shevelev A, Tkachuk V. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J Biol Chem. 2000 Jun 2;275(22):16450-8. https://doi.org/10.1074/jbc.M909080199Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996 Apr 1;15(7):1572-82.Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996 Apr 1;15(7):1572-82.Limongi P, Resnati M, Hernandez-Marrero L, Cremona O, Blasi F, Fazioli F. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. FEBS Lett. 1995 Aug 7;369(2-3):207-11. https://doi.org/10.1016/0014-5793(95)00742-rLimongi P, Resnati M, Hernandez-Marrero L, Cremona O, Blasi F, Fazioli F. Biosynthesis and apical localization of the urokinase receptor in polarized MDCK epithelial cells. FEBS Lett. 1995 Aug 7;369(2-3):207-11. https://doi.org/10.1016/0014-5793(95)00742-rMyöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993 Sep;41(9):1291-301. https://doi.org/10.1177/41.9.8394852Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem. 1993 Sep;41(9):1291-301. https://doi.org/10.1177/41.9.8394852Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990 Aug;111(2):783-92. https://doi.org/10.1083/jcb.111.2.783Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990 Aug;111(2):783-92. https://doi.org/10.1083/jcb.111.2.783Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004Aug; 25(8):450-5. https://doi.org/10.1016/j.it.2004.06.004Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004Aug; 25(8):450-5. https://doi.org/10.1016/j.it.2004.06.004Gyetko MR, Sud S, Sonstein J, Polak T, Sud A, Curtis JL. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol. 2001 Nov 15;167(10):5539-42. https://doi.org/10.4049/jimmunol.167.10.5539Gyetko MR, Sud S, Sonstein J, Polak T, Sud A, Curtis JL. Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA. J Immunol. 2001 Nov 15;167(10):5539-42. https://doi.org/10.4049/jimmunol.167.10.5539Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018 Feb 12;8:24. https://doi.org/10.3389/fonc.2018.00024Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications. Front Oncol. 2018 Feb 12;8:24. https://doi.org/10.3389/fonc.2018.00024Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, Berger DH. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia. 2010 Nov;12(11):856-65. https://doi.org/10.1593/neo.10224Belaguli NS, Aftab M, Rigi M, Zhang M, Albo D, Berger DH. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression. Neoplasia. 2010 Nov;12(11):856-65. https://doi.org/10.1593/neo.10224Huang WS, Chin CC, Chen CN, Kuo YH, Chen TC, Yu HR, Tung SY, Shen CH, Hsieh YY, Guo SE, Shi CS, Liu TJ, Kuo HC. Stromal cell-derived factor-1/CXC receptor 4 and β1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells. J Cell Physiol. 2012 Mar;227(3):1114-22. https://doi.org/10.1002/jcp.22831Huang WS, Chin CC, Chen CN, Kuo YH, Chen TC, Yu HR, Tung SY, Shen CH, Hsieh YY, Guo SE, Shi CS, Liu TJ, Kuo HC. Stromal cell-derived factor-1/CXC receptor 4 and β1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells. J Cell Physiol. 2012 Mar;227(3):1114-22. https://doi.org/10.1002/jcp.22831

The authors declare that there are no conflicts of interest present.